Jyothy Labs Q2 Review — Weak Quarter Despite Volume Growth, Says Motilal Oswal Maintaining 'Neutral' Stance

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

We cut our EPS estimates by 2%-3% each for FY26E-28E.

We believe that while H2 FY26 will be better than H1 FY26 for most FMCG names, elevated competitive intensity could limit Jyothy Laboratories Ltd.’s growth in the near term.

Market share gains, the success of new launches, a recovery in personal care, and the turnaround of HI portfolio will be crucial for Jyothy Labs’ earnings growth.

Jyothy Labs’ margin expansion beyond ~18% is also constrained by its focus on the mass and rural segments. Therefore, we believe its growth potential is adequately priced in at the current valuation.

We reiterate our Neutral rating on the stock with a target price of Rs 350 (premised on 30x Sep’27E P/E).

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.